Advertisement

Combined Modality Therapy in Locally Advanced Breast Cancer

  • Silvia C. Formenti
  • Matthew Volm
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

The management of locally advanced breast cancer requires the integration of surgery, chemotherapy, and radiation therapy. This chapter summarizes the existing experience and addresses some of the remaining issues in combined modality therapy of locally advanced and inflammatory breast cancer.

Keywords

Breast Cancer Overall Survival Clin Oncol Advanced Breast Cancer Radiat Oncol Biol Phys 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schaake-Koning C, van der Linden EH, Hart G, Engelsman E. Adjuvant chemo-and hormonal therapy in locally advanced breast cancer: a randomized clinical study. Int J Radiat Oncol Biol Phys 1985; 11: 1759–1763.PubMedCrossRefGoogle Scholar
  2. 2.
    Rubens RD, Bartelink H, Engelsman E, et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792). Eur J Cancer Clin Oncol 1989; 25: 667–678.PubMedCrossRefGoogle Scholar
  3. 3.
    Grohn P, Heinonen E, Klefstrom P, Tarkkanen J. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 1984; 54: 670–674.PubMedCrossRefGoogle Scholar
  4. 4.
    Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310–1317.PubMedGoogle Scholar
  5. 5.
    Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III nonsmall-cell lung cancer. J Clin Oncol 1999; 17: 2692–2699.PubMedGoogle Scholar
  6. 6.
    Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606–1613.PubMedGoogle Scholar
  7. 7.
    Johnston PG, Lenz HJ, Leichman CG, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407–1412.PubMedGoogle Scholar
  8. 8.
    Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays. Int J Radiat Oncol, Biol, Phy 1982; 8: 1923–1933.Google Scholar
  9. 9.
    Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA- directed effects. Int J Radiat Oncol Biol Phys 1994; 29: 519–523.PubMedCrossRefGoogle Scholar
  10. 10.
    Janjan NA, Crane CN, Feig BW, et al. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2000; 47: 713–718.PubMedCrossRefGoogle Scholar
  11. 11.
    Cafiero F, Gipponi M, Peressini A, Bertoglio S, Lionetto R. Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer. J Surg Oncol 2000; 75: 80–88.PubMedCrossRefGoogle Scholar
  12. 12.
    Jabboury K, Holmes FA, Hortobagyi G. 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 1989; 64: 793–797.PubMedCrossRefGoogle Scholar
  13. 13.
    Formenti SC, Uziely B, Dunnington G, et al. Continuous infusion (ci) 5-fluorouracil (FU) with radiation in locally advanced breast cancer: clinicopathological and biological correlates (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1995; 14: A358.Google Scholar
  14. 14.
    Formenti SC, Dunnington G, Uzieli B, et al. Original p.53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol, Biol, Physics 1997; 39: 1059–1068.Google Scholar
  15. 15.
    Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460–469.PubMedGoogle Scholar
  16. 16.
    Merajver SD, Weber BL, Cody R, et al. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: the University of Michigan experience. J Clin Oncol 1997; 15: 2873–2881.PubMedGoogle Scholar
  17. 17.
    Morrell LE, Lee YJ, Hurley J, et al. A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. Cancer 1998; 82: 503–511.PubMedCrossRefGoogle Scholar
  18. 18.
    Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547–552.PubMedGoogle Scholar
  19. 19.
    Karlsson YA, Malmstrom PO, Hatschek T, et al. Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications. Cancer 1998; 83: 936–947.PubMedCrossRefGoogle Scholar
  20. 20.
    Zambetti M, Oriana S, Quattrone P, et al. Combined sequential approach in locally advanced breast cancer. Annals Oncol 1999; 10: 305–310.CrossRefGoogle Scholar
  21. 21.
    Wahl AF, Donaldson KL, Fairchild C, et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72–79.PubMedCrossRefGoogle Scholar
  22. 22.
    Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995; 1: 506–526.Google Scholar
  23. 23.
    Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6: 50–56.PubMedGoogle Scholar
  24. 24.
    Milas L, Hunter NR, Kurdoglu B, et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 1995; 35: 297–303.PubMedCrossRefGoogle Scholar
  25. 25.
    Symmans W, Volm M, Shapiro R, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000; 6: 4610–4617.PubMedGoogle Scholar
  26. 26.
    Formenti SC, Symmans WF, Volm M, et al. Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol 1999; 9: 34–42.PubMedGoogle Scholar
  27. 27.
    Horwitz S, Zambetti M, Oriana S, et al. Taxol: Mechanisms of action and resistance. JNCI Monographs 1993; 15: 55–61.Google Scholar
  28. 28.
    Kavallaris M, Kuo DYS, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100: 1282–1293.PubMedCrossRefGoogle Scholar
  29. 29.
    Nguyen HL, Chari S, Gruber D, Lue CM, Chapin SJ, Bulinski JC. Overexpression of full-or partial-length MAP4 stabilizes microtubules and alters cell growth. J Cell Sci 1997; 110: 281–294.PubMedGoogle Scholar
  30. 30.
    Zhang C. Genetic susceptibility to microtubule-active cancer chemotherapeutic drugs: p53 action and the role of MAP4. Proceedings of AACR 1998; 1308.Google Scholar
  31. 31.
    Haldar S, Chintapalli J, Croce CM. Taxol induces Bc1–2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56: 1253–1255.PubMedGoogle Scholar
  32. 32.
    Montgomery RB, Guzman J, O’Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 2000; 275:17, 358–17, 363.Google Scholar
  33. 33.
    Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/ neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999; 59: 1347–1355.PubMedGoogle Scholar
  34. 34.
    Formenti S, Low HER 2/NEU Gene Expression is Associated with Pathological Response to Primary Paclitaxel and Radiation in Locally Advanced Cancer (LABC). Proceedings of ASTRO 2000; 63.Google Scholar
  35. 35.
    Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93–100.PubMedGoogle Scholar
  36. 36.
    Formenti SC, Cohen D, Tsao-Wei DD, et al. Clinical Course of Locally Advanced Breast Cancer (LABC) Patients with pathological response to primary concurrent 5-fluorouracil and radiation (FU/ RT). Im J Radiat Oncol Biol Phys 2001; 51: 195–196 (abstract 1039).CrossRefGoogle Scholar
  37. 37.
    Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin NAm 1995; 4: 715–734.Google Scholar
  38. 38.
    Maloisel F, Dufour P, Bergerat JP, et al. Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 1990; 65: 851–855.PubMedCrossRefGoogle Scholar
  39. 39.
    Viens P, Penault-Llorca F, Jacquemier J, et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 1998; 21: 249–254.PubMedCrossRefGoogle Scholar
  40. 40.
    Cagnoni PJ, Nieto Y, Shpall EJ, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 1998; 16: 1661–1668.PubMedGoogle Scholar
  41. 41.
    Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer 1993; 67: 594–601.PubMedCrossRefGoogle Scholar
  42. 42.
    Fields JN, Perez CA, Kuske RR, Fineberg BB, Bartlett N. Inflammatory carcinoma of the breast: treatment results on 107 patients. Int J Radiat Oncol Biol Phys 1989; 17: 249–255.PubMedCrossRefGoogle Scholar
  43. 43.
    Thorns WW Jr, McNeese MD, Fletcher GH, Buzdar AU, Singletary SE, Oswald MJ. Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 1989; 17: 739–745.CrossRefGoogle Scholar
  44. 44.
    Rouesse J, Friedman S, Sarrazin D, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986; 4: 1765–1771.PubMedGoogle Scholar
  45. 45.
    Thomas E, Buzdar A, Hortobagyi G, et al. Long-Term Follow Up of Stage III Breast Cancer-Combined Modality Treatment with Anthracycline Containing Chemotherapy (CT): The MD Anderson Experience (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1999; 18: A284.Google Scholar
  46. 46.
    Honkoop AH, Luykx-de Bakker SA, Hoekman K, et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist 1999; 4: 106–111.PubMedGoogle Scholar
  47. 47.
    Dhingra K, Esparza-Guerra L, Valero V, et al. A Phase III Randomized Trial of Dose-Intensive, Neoadjuvant 5FU, Doxorubicin, Cyclophosphamide (FAC) with G-CSF (filgrastim) in Locally Advanced Breast Cancer (LABC)-Efficacy and Safety Data (Meeting abstract). Proc Anna Meet Am Soc Clin Oncol 1999; 18: A278.Google Scholar
  48. 48.
    Eltahir A, Heys SD, Hutcheon AW, et al. Treatment of large and locally advanced breast cancers using neoadjuvant chemotherapy. Am J Surg 1998; 175: 127–132.PubMedCrossRefGoogle Scholar
  49. 49.
    De Matteis A, Montella M, Iannuzzo M, et al. Multimodal treatment strategy for locally advanced breast cancer. J Chemother 1998; 10: 476–483.PubMedGoogle Scholar
  50. 50.
    Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73: 362–369.PubMedCrossRefGoogle Scholar
  51. 51.
    Ayash U, Elias A, Ibrahim J, et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol 1998; 16: 1000–1007.PubMedGoogle Scholar
  52. 52.
    Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 1998; 176: 502–509.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Silvia C. Formenti
  • Matthew Volm

There are no affiliations available

Personalised recommendations